• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance 0

Alexion To Acquire Sweden’s Wilson Therapeutics For $855M In Cash

By Kurt Osterberg · On April 11, 2018

Alexion Pharmaceuticals (ALXN) and Wilson Therapeutics AB announced that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary.

Wilson Therapeutics, based in Stockholm, Sweden, develops therapies for patients with rare copper-mediated disorders. The company’s WTX101 is in Phase 3 development as a treatment for Wilson disease. Alexion will acquire Wilson Therapeutics through a tender offer that was launched this morning whereby Alexion, through a wholly owned subsidiary, has offered SEK 232 in cash for each outstanding share of Wilson Therapeutics. The total equity value of the transaction amounts to approximately $855M. The Independent Committee of Wilson’s board has unanimously recommended Wilson Therapeutics shareholders accept the offer and Alexion’s board also unanimously approved the offer. Alexion has obtained shareholder support agreements from the four largest shareholders accounting for 57.4% of Wilson Therapeutics’ outstanding shares and two additional shareholders accounting for 8.7% for a total of 66.1% of Wilson Therapeutics’ outstanding shares, to the effect that these shareholders have undertaken to accept the offer on certain terms. In addition, Polar Capital, holding 7.3% of Wilson Therapeutics’ outstanding shares, has expressed its support for, and intends to accept, the offer, for a total support of 73.4%. The acquisition of Wilson Therapeutics requires approval of relevant regulatory authorities, and Alexion expects to obtain such approvals prior to the end of the acceptance period. The tender offer is expected to complete and the transaction is expected to close in Q2 of 2018. Alexion intends to finance the acquisition through cash on hand.

BofA Merrill Lynch is acting as Alexion’s lead financial advisor.
 

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    Lack of Attention to This “Big Rock” in Your Business is Costing You

  • Finance

    SDGs in 2021: Where Do We Go From Here?

  • Finance

    How Microlearning Can be Used to Improve Employee Training Retention

No Comments

Leave a reply Cancel reply

Top Finance

  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce
  • Hedge Funds In The US Hedge Funds In The US
  • One Ring To Rule Them All One Ring To Rule Them All
  • Kanban vs Scrum: Understanding the Tools for Agile Success Kanban vs Scrum: Understanding the Tools for Agile Success
  • Samsung Galaxy Note 9 Review Samsung Galaxy Note 9 Review

New Posts

  • Lack of Attention to This “Big Rock” in Your Business is Costing You

    Lack of Attention to This “Big Rock” in Your Business is Costing You

    February 25, 2021
  • SDGs in 2021: Where Do We Go From Here?

    SDGs in 2021: Where Do We Go From Here?

    February 25, 2021
  • How Microlearning Can be Used to Improve Employee Training Retention

    How Microlearning Can be Used to Improve Employee Training Retention

    February 25, 2021
  • Leaders: A Roadmap For Behavior Change

    Leaders: A Roadmap For Behavior Change

    February 25, 2021
  • 7 Modern Strategies to Make Remote Teams Work in 2021

    7 Modern Strategies to Make Remote Teams Work in 2021

    February 25, 2021
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018-2021 NJCEE. All Rights Reserved.